Adverse event
Adverse event – any untoward medical occurrence in a patient administered a medicinal product and which does not necessairly have to have a casual relationship with this treatment.
How to report an adverse reaction
- By electronic means using the online form at www.polpharma.pl
- By phone at: +48 22 364 61 00
- By email to the address: phv@polpharma.com
- By letter to the address:
Zakłady Farmaceutyczne „POLPHARMA”, office in Warsaw
6 Bobrowiecka Str.
00-728 Warsaw, Poland
Dział Nadzoru Nad Bezpieczeństwem Farmakoterapii (Pharmacovigilance & Medical Information Department)
- By fax:+48 22 364 61 66
What the report should contain
Details of the person experiencing the adverse reaction
Specify patient’s identifiers, e.g. initials, gender or age. Also, information on height and body mass are helpful – in particular for children and adults with atypical height or body mass.
Product details
Specify the name of the drug, cosmetic or medical device suspected of causing the adverse reaction. A situation may arise where the patient is taking more than one product. In such a situation, specify the names of all used products. Information on the product dose is important, e.g. 200 mg tablet or 5 mg/ml syrup, and the manner of drug use – how many times a day and in what doses. Some products are used chronically. It is worth mentioning this. It is important because if the patient has been taking the relevant product for years without experiencing any adverse reactions, and if such adverse reactions occur with the start of use of another product, it may be suspected that the adverse reaction is caused by the new product or that the reaction has been caused e.g. by interaction between the products.
Description of the adverse reaction
Describe the reaction in as much detail as possible, including its severity, duration – and, if it subsided, describe whether the reaction subsided on its own or as a result of the administered treatment. It is important to provide the reason for drug use, e.g. toothache, stomach ailments, hypertension, etc. If the reaction did not subside, specify whether it is receding or intensifying, whether any treatment is being administered, whether the product has caused any lasting effects in the patient.
Reporting person’s details
Specify the details, including forename, surname, full address or telephone number or email.
Additional information
If such details are available, specify whether the product which caused the adverse reaction had already been used in the past and whether also then it caused a similar reaction. Information on patient’s allergies is important as well. If the report concerns an adverse reaction in a newborn, specify the names of the products taken by the child’s mother during pregnancy. Not always all the details are available at the time of submitting the case report. In such a case, any additional information should be provided once it becomes available. It is recommended to specify whether this information is supplementary to any case report that has already been submitted.
Where to report an adverse event
Patients or their caregivers may report adverse events to:
- a physician, pharmacist, nurse or other healthcare professionals
- the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products (www.urpl.gov.pl)
- a pharmaceutical company responsible for the drug
Healthcare professionals (a physician, pharmacist, nurse) are required to report adverse events to:
- the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products (www.urpl.gov.pl)
- a pharmaceutical company responsible for the drug.
Educational materials and safety communications
Educational materials supplement the information included in product information (Summary of Product Characteristics, patient leaflet) and improve the conditions of use of medicinal products by having a favorable influence on the activities of healthcare professionals (physicians, pharmacists, nurses), patients or their caregivers. They focus on achievable goals and provide clear and concise information describing the activities to be taken in order to prevent and minimize any substantial risks and to optimize the risk to benefit ratio.
- Educational materials for the patient
- Educational materials and safety communications for healthcare professionals
Educational materials for the patient
They increase awareness of the early symptoms of specific adverse reactions and how best to proceed in case of their occurrence. They may also provide information on proper administration of the product or remind of an important activity.
Adrenalina WZF adrenalina
Adrenalina WZF Junior adrenalina
Maxigra Go sildenafil
Momester Nasal mometazon (furoinian mometazonu)
Pola Ring etynyloestradiol + etonogestrel
Voriconazol Polpharma voriconazole
Educational materials and safety communications for healthcare professionals
They provide specific recommendations on the use / contraindications / warnings related to the product and specific significant risks that require additional risk minimization measures to be applied (e.g. product dosage, special procedures related to product administration or details to be provided to the patients).
Adrenalina WZF adrenalina
Adrenalina WZF Junior adrenalina
Maxigra Max syldenafil 50 mg, tabletki powlekane
Momester Nasal mometazon (furoinian mometazonu)
Tenofovir Polpharma tenofovir (dizoproksyl tenofowiru)
- Broszura edukacyjna dotycząca zastosowania produktu leczniczego u chorych w wieku od 12 do < 18 lat zakażonych wirusem zapalenia wątroby typu B (HBV)
- Broszura edukacyjna dotycząca zwiększonego ryzyka zaburzeń czynności nerek u pacjentów zakażonych wirusem zapalenia wątroby typu B (HBV)
- Broszura edukacyjna dotycząca zastosowania produktu leczniczego u chorych w wieku od 12 do < 18 lat zakażonych wirusem HIV-1
- Broszura edukacyjna dotycząca zwiększonego ryzyka zaburzeń czynności nerek u pacjentów zakażonych wirusem HIV-1
- Kalkulator oznaczania klirensu kreatyniny
Voriconazol Polpharma worykonazol
Announcements
Most recent information and guidelines on the use of Polpharmа Group products in infections caused by coronavirus.